FMR1 gray-zone alleles: Association with Parkinson's disease in women?

Movement Disorders

Volumn 26, Issue 10, 2011, Pages 1900-1906

  Hall, Deborah A ^a   Berry Kravis, Elizabeth ^a   Zhang, Wenting ^b   Tassone, Flora ^b,c   Spector, Elaine ^d   Zerbe, Gary ^d   Hagerman, Paul J ^c,d   Ouyang, Bichun ^a   Leehey, Maureen A ^d  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Fragile X mental retardation 1; Fragile X associated tremor ataxia syndrome; Genetics; Parkinson's disease; Parkinsonism

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CEREBELLAR ATAXIA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GRAY ZONE ALLELE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; TREMOR;

ADULT; AGED; ALLELES; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEX FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 80052264026     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23755     Document Type: Article

References (45)

1. Sullivan AK, Marcus M, Epstein M, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005; 20: 402-412.
2. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004; 291: 460-469.
3. Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in FXTAS. Neurology 2008; 70: 1397-1402.
4. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72: 869-878.
5. Ennis S, Murray A, Youings S, et al. An investigation of FRAXA intermediate allele phenotype in a longitudinal sample. Ann Hum Genet 2006; 70: 170-180.
6. Sherman S, Marsteller F, Abramoqitz A, Scott E, Leslie M, Bergman J. Cognitive and behavioral performance among FMR1 high-repeat allele carriers surveyed from special education classes. Am J Med Genet 2002; 114: 458-465.
7. Loesch DZ, Khaniani MS, Slater, HR et al. Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism. Clin Genet 2009; 76: 471-476.
8. Dombrowski C, Levesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10, 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Med Genet 2002; 11: 371-378.
9. Rousseau F, Rouillard P, Morel M, Khandjian EW, Morgan K. Prevalence of carriers of premutation-size alleles of the FMR1 gene-and implications for the population genetics of the fragile X syndrome. Am J Hum Genet 1995; 57: 1006-1018.
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
11. Siesling S, Zwinderman AH, van Vugt JP, Kieburtz K, Roos RA. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale. Mov Disord 1997; 12: 229-234.
12. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci 1997; 145: 205-211.
13. Fahn S, Tolosa E, Marin C. Clinical Rating Scale for Tremor. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore: Urban & Schwartzenberg; 1987: 225-234.
14. Louis ED, Ford B, Lee H, Andrews H. Does a screening questionnaire for essential tremor agree with the physician's examination? Neurology 1998; 50: 1351-1357.
15. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 56: 33-39.
16. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple systems atrophy. J Neurol Sci 1999 163: 94-98.
17. Tolosa E, Valldeoriola F, Cruz-Sanchez F. Progressive supranuclear palsy: clinical and pathological diagnosis. Eur J Neurol 1995; 2: 258-273.
18. Lang AE, Riley DE, Bergeron C. Cortical-basal ganglionic degeneration. In: Calne DB, ed. Neurodegeneration Diseases. Philadelphia: WB Saunders; 1994: 877-894.
19. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 113-124.
20. Tassone F. Pan R. Amiri K. Taylor AK. Hagerman PJ. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Molec Diagnostics 2008; 10: 43-49.
21. Levinson G, Maddalena A, Palmer FT, et al. Improved sizing of fragile X CCG repeats by nested polymerase chain reaction. Am J Med Genet 1994; 51: 527-534.
22. Hall DA, Berry-Kravis E, Jacquemont S, et al. Initial diagnoses given to persons with the fragile x-associated tremor/ataxia syndrome (FXTAS). Neurology 2005; 65: 299-301.
23. Kunst CB, Zerylnick C, Karickhoff L, et al. FMR1 in global populations. Am J Hum Genet 1996; 58: 513-522.
24. Barros-Nunez P, Rosales-Reynoso MA, Sandoval L, et al. Genetic variation of the FMR1 gene among four Mexican populations: Mestizo, Huichol, Purepecha, and Tarahumara. Am J Hum Biol 2008; 20: 259-263.
25. Hall DA, Howard K, Hagerman RJ, Leehey MA. Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Park Rel Dis Parkinsonism Relat Disord 2009; 15: 156-159.
26. Hall DA, Hagerman RJ, Hagerman PJ, Jacquemont S, Leehey MA. Prevalence of FMR1 repeat expansions in movement disorders: a systematic review. Neuroepidemiology 2006; 26: 151-155.
27. Hedrich K, Pramstaller P, Stubke K, et al. Premutations in the FMR1 gene as a modifying factor in Parkin-associated Parkinson's disease? Mov Disord 2005; 20: 1060-1062.
28. Deng H, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. JAMA 2004; 292: 1685-1868.
29. Kraff J, Tang H, Cilia R, et al. Screen for excess FMR1 premutation alleles among males with parkinsonism. Arch Neurol 2007; 64: 1002-1006.
30. Cilia R, Kraff J, Canesi M, et al. Screening for the presence of FMR1 premutation alleles in women with parkinsonism. Arch Neurol 2009; 66: 244-249.
31. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 2001: 69: 351-360.
32. Otsuka S, Sakamoto Y, Siomi H, et al. Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain Dev 2010; 32: 110-114.
33. Kurz MW, Schlitter AM, Klenk Y, et al. FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study. J Geriatr Psychiatry Neurol 2007; 20: 89-92.
34. Semaka A, Creighton S, Warby S, Hayden MR. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet 2006; 70: 283-294.
35. Groen JL, de Bie RM, Foncke EM, Roos RA, Leenders KL, Tijssen MA. Late-onset Huntington disease with intermediate CAG repeats: true or false? J Neurol Neurosurg Psychiatry 2010; 81: 228-230.
36. Alonso I, Jardim LB, Artigalas O, et al. Reduced penetrance of intermediate size alleles in spinocerebellar ataxia type 10. Neurology 2006; 66: 1602-1604.
37. Ragonese P, D'Amelio M, Salemi G, et al. Risk of Parkinson disease in women effect of reproductive characteristics. Neurology 2004; 62: 2010-2014.
38. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001; 16: 830-837.
39. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70: 200-209.
40. Ragonese P, D'Amelio MD, Savettieri G. Implications for estrogens in Parkinson's disease. Ann N Y Acad Sci 2006; 1089: 373-382.
41. Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet 2005; 117: 376-382.
42. Bodega B, Bione S, Dalprà L, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod 2006; 21: 952-957.
43. Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000; 91: 144-152.
44. Loesch DZ, Bui QM, Huggins RM, Mitchell RJ, Hagerman RJ. Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raise, and correlate with the number of CGG repeats. J Med Genet 2007; 44: 200-204.
45. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Molec Genet 2010; 19: R83-R89.